Magnetic Paclitaxel Nanoparticles Inhibit Glioma Growth and Improve the Survival of Rats Bearing Glioma Xenografts
Paclitaxel has fared poorly in clinical trials against brain glioma. We hypothesized that superparamagnetic nanocarriers may enhance its bioactivities by delivering it into the brain. The magnetic paclitaxel nanoparticles (MPNPs) were fabricated and their cytotoxicity against glioma was tested both...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2010-06, Vol.30 (6), p.2217-2223 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2223 |
|---|---|
| container_issue | 6 |
| container_start_page | 2217 |
| container_title | Anticancer research |
| container_volume | 30 |
| creator | Zhao, Ming Liang, Chao Li, Anmin Chang, Jin Wang, Hanjie Yan, Runmin Zhang, Jiajing Tai, Junli |
| description | Paclitaxel has fared poorly in clinical trials against brain glioma. We hypothesized that superparamagnetic nanocarriers may enhance its bioactivities by delivering it into the brain.
The magnetic paclitaxel nanoparticles (MPNPs) were fabricated and their cytotoxicity against glioma was tested both in vitro and in glioma-bearing rats.
MPNPs exhibited superparamagnetism and produced an extended release of paclitaxel over 15 days in vitro. They were easily internalized into glioma cells and exerted remarkable toxicity, as free paclitaxel did. Furthermore, after intravenous injection of MPNPs to glioma-bearing rats and magnetic targeting with a 0.5 T magnet, drug content increased for 6- to 14-fold in implanted glioma and 4.6- to 12.1-fold in the normal brain compared to free paclitaxel. The survival of glioma-bearing rats was significantly prolonged after magnetic targeting therapy with MPNPs.
MPNPs efficiently delivered paclitaxel into brain glioma by magnetic targeting and enhance its antitumor activity. They are promising for local chemotherapy for malignant glioma. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_734005564</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734005564</sourcerecordid><originalsourceid>FETCH-LOGICAL-p240t-3db32ce19fbe5c6fc3d4cb917fba5a9ecf66b02b6841c6341665061ee2ba398e3</originalsourceid><addsrcrecordid>eNpF0G1LwzAQB_AiipvTryB5I74qpE2Tri916BzMB3wA35VLetkiaTqTdOq3t-CGcHBw_O44_gfJOCurLC05o4fJmOacpiWlfJSchPBBqRDVlB0no5wKnrEyHyf-HlYOo1HkCZQ1Eb7Rkgdw3Qb8MLUYyMKtjTSRzK3pWiBz333FNQHXkEW78d0WSVwjeen91mzBkk6TZ4iBXCN441b7tXd03cqDjuE0OdJgA57t-iR5u715nd2ly8f5Yna1TDd5QWPKGslyhVmlJXIltGJNoWSVlVoChwqVFkLSXIppkSnBikwITkWGmEtg1RTZJLn8uzs8-dljiHVrgkJrwWHXh7pkxRANF8Ugz3eyly029cabFvxPvY9pABc7AEGB1R6cMuHfMUorNtQvW1lzPw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734005564</pqid></control><display><type>article</type><title>Magnetic Paclitaxel Nanoparticles Inhibit Glioma Growth and Improve the Survival of Rats Bearing Glioma Xenografts</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Zhao, Ming ; Liang, Chao ; Li, Anmin ; Chang, Jin ; Wang, Hanjie ; Yan, Runmin ; Zhang, Jiajing ; Tai, Junli</creator><creatorcontrib>Zhao, Ming ; Liang, Chao ; Li, Anmin ; Chang, Jin ; Wang, Hanjie ; Yan, Runmin ; Zhang, Jiajing ; Tai, Junli</creatorcontrib><description>Paclitaxel has fared poorly in clinical trials against brain glioma. We hypothesized that superparamagnetic nanocarriers may enhance its bioactivities by delivering it into the brain.
The magnetic paclitaxel nanoparticles (MPNPs) were fabricated and their cytotoxicity against glioma was tested both in vitro and in glioma-bearing rats.
MPNPs exhibited superparamagnetism and produced an extended release of paclitaxel over 15 days in vitro. They were easily internalized into glioma cells and exerted remarkable toxicity, as free paclitaxel did. Furthermore, after intravenous injection of MPNPs to glioma-bearing rats and magnetic targeting with a 0.5 T magnet, drug content increased for 6- to 14-fold in implanted glioma and 4.6- to 12.1-fold in the normal brain compared to free paclitaxel. The survival of glioma-bearing rats was significantly prolonged after magnetic targeting therapy with MPNPs.
MPNPs efficiently delivered paclitaxel into brain glioma by magnetic targeting and enhance its antitumor activity. They are promising for local chemotherapy for malignant glioma.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 20651372</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Animals ; Antineoplastic Agents, Phytogenic - administration & dosage ; Biological and medical sciences ; Brain Neoplasms - drug therapy ; Brain Neoplasms - mortality ; Brain Neoplasms - pathology ; Cell Line, Tumor ; Cerebral Cortex - metabolism ; Glioma - drug therapy ; Glioma - mortality ; Glioma - pathology ; Humans ; Magnetics ; Medical sciences ; Nanoparticles - administration & dosage ; Neurology ; Paclitaxel - administration & dosage ; Paclitaxel - chemistry ; Paclitaxel - metabolism ; Rats ; Rats, Sprague-Dawley ; Solubility ; Tumors ; Tumors of the nervous system. Phacomatoses ; Xenograft Model Antitumor Assays</subject><ispartof>Anticancer research, 2010-06, Vol.30 (6), p.2217-2223</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23009309$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20651372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Ming</creatorcontrib><creatorcontrib>Liang, Chao</creatorcontrib><creatorcontrib>Li, Anmin</creatorcontrib><creatorcontrib>Chang, Jin</creatorcontrib><creatorcontrib>Wang, Hanjie</creatorcontrib><creatorcontrib>Yan, Runmin</creatorcontrib><creatorcontrib>Zhang, Jiajing</creatorcontrib><creatorcontrib>Tai, Junli</creatorcontrib><title>Magnetic Paclitaxel Nanoparticles Inhibit Glioma Growth and Improve the Survival of Rats Bearing Glioma Xenografts</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Paclitaxel has fared poorly in clinical trials against brain glioma. We hypothesized that superparamagnetic nanocarriers may enhance its bioactivities by delivering it into the brain.
The magnetic paclitaxel nanoparticles (MPNPs) were fabricated and their cytotoxicity against glioma was tested both in vitro and in glioma-bearing rats.
MPNPs exhibited superparamagnetism and produced an extended release of paclitaxel over 15 days in vitro. They were easily internalized into glioma cells and exerted remarkable toxicity, as free paclitaxel did. Furthermore, after intravenous injection of MPNPs to glioma-bearing rats and magnetic targeting with a 0.5 T magnet, drug content increased for 6- to 14-fold in implanted glioma and 4.6- to 12.1-fold in the normal brain compared to free paclitaxel. The survival of glioma-bearing rats was significantly prolonged after magnetic targeting therapy with MPNPs.
MPNPs efficiently delivered paclitaxel into brain glioma by magnetic targeting and enhance its antitumor activity. They are promising for local chemotherapy for malignant glioma.</description><subject>Animals</subject><subject>Antineoplastic Agents, Phytogenic - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - pathology</subject><subject>Cell Line, Tumor</subject><subject>Cerebral Cortex - metabolism</subject><subject>Glioma - drug therapy</subject><subject>Glioma - mortality</subject><subject>Glioma - pathology</subject><subject>Humans</subject><subject>Magnetics</subject><subject>Medical sciences</subject><subject>Nanoparticles - administration & dosage</subject><subject>Neurology</subject><subject>Paclitaxel - administration & dosage</subject><subject>Paclitaxel - chemistry</subject><subject>Paclitaxel - metabolism</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Solubility</subject><subject>Tumors</subject><subject>Tumors of the nervous system. Phacomatoses</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0G1LwzAQB_AiipvTryB5I74qpE2Tri916BzMB3wA35VLetkiaTqTdOq3t-CGcHBw_O44_gfJOCurLC05o4fJmOacpiWlfJSchPBBqRDVlB0no5wKnrEyHyf-HlYOo1HkCZQ1Eb7Rkgdw3Qb8MLUYyMKtjTSRzK3pWiBz333FNQHXkEW78d0WSVwjeen91mzBkk6TZ4iBXCN441b7tXd03cqDjuE0OdJgA57t-iR5u715nd2ly8f5Yna1TDd5QWPKGslyhVmlJXIltGJNoWSVlVoChwqVFkLSXIppkSnBikwITkWGmEtg1RTZJLn8uzs8-dljiHVrgkJrwWHXh7pkxRANF8Ugz3eyly029cabFvxPvY9pABc7AEGB1R6cMuHfMUorNtQvW1lzPw</recordid><startdate>20100601</startdate><enddate>20100601</enddate><creator>Zhao, Ming</creator><creator>Liang, Chao</creator><creator>Li, Anmin</creator><creator>Chang, Jin</creator><creator>Wang, Hanjie</creator><creator>Yan, Runmin</creator><creator>Zhang, Jiajing</creator><creator>Tai, Junli</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20100601</creationdate><title>Magnetic Paclitaxel Nanoparticles Inhibit Glioma Growth and Improve the Survival of Rats Bearing Glioma Xenografts</title><author>Zhao, Ming ; Liang, Chao ; Li, Anmin ; Chang, Jin ; Wang, Hanjie ; Yan, Runmin ; Zhang, Jiajing ; Tai, Junli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p240t-3db32ce19fbe5c6fc3d4cb917fba5a9ecf66b02b6841c6341665061ee2ba398e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Antineoplastic Agents, Phytogenic - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - pathology</topic><topic>Cell Line, Tumor</topic><topic>Cerebral Cortex - metabolism</topic><topic>Glioma - drug therapy</topic><topic>Glioma - mortality</topic><topic>Glioma - pathology</topic><topic>Humans</topic><topic>Magnetics</topic><topic>Medical sciences</topic><topic>Nanoparticles - administration & dosage</topic><topic>Neurology</topic><topic>Paclitaxel - administration & dosage</topic><topic>Paclitaxel - chemistry</topic><topic>Paclitaxel - metabolism</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Solubility</topic><topic>Tumors</topic><topic>Tumors of the nervous system. Phacomatoses</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Ming</creatorcontrib><creatorcontrib>Liang, Chao</creatorcontrib><creatorcontrib>Li, Anmin</creatorcontrib><creatorcontrib>Chang, Jin</creatorcontrib><creatorcontrib>Wang, Hanjie</creatorcontrib><creatorcontrib>Yan, Runmin</creatorcontrib><creatorcontrib>Zhang, Jiajing</creatorcontrib><creatorcontrib>Tai, Junli</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Ming</au><au>Liang, Chao</au><au>Li, Anmin</au><au>Chang, Jin</au><au>Wang, Hanjie</au><au>Yan, Runmin</au><au>Zhang, Jiajing</au><au>Tai, Junli</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Magnetic Paclitaxel Nanoparticles Inhibit Glioma Growth and Improve the Survival of Rats Bearing Glioma Xenografts</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2010-06-01</date><risdate>2010</risdate><volume>30</volume><issue>6</issue><spage>2217</spage><epage>2223</epage><pages>2217-2223</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Paclitaxel has fared poorly in clinical trials against brain glioma. We hypothesized that superparamagnetic nanocarriers may enhance its bioactivities by delivering it into the brain.
The magnetic paclitaxel nanoparticles (MPNPs) were fabricated and their cytotoxicity against glioma was tested both in vitro and in glioma-bearing rats.
MPNPs exhibited superparamagnetism and produced an extended release of paclitaxel over 15 days in vitro. They were easily internalized into glioma cells and exerted remarkable toxicity, as free paclitaxel did. Furthermore, after intravenous injection of MPNPs to glioma-bearing rats and magnetic targeting with a 0.5 T magnet, drug content increased for 6- to 14-fold in implanted glioma and 4.6- to 12.1-fold in the normal brain compared to free paclitaxel. The survival of glioma-bearing rats was significantly prolonged after magnetic targeting therapy with MPNPs.
MPNPs efficiently delivered paclitaxel into brain glioma by magnetic targeting and enhance its antitumor activity. They are promising for local chemotherapy for malignant glioma.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>20651372</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2010-06, Vol.30 (6), p.2217-2223 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734005564 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Animals Antineoplastic Agents, Phytogenic - administration & dosage Biological and medical sciences Brain Neoplasms - drug therapy Brain Neoplasms - mortality Brain Neoplasms - pathology Cell Line, Tumor Cerebral Cortex - metabolism Glioma - drug therapy Glioma - mortality Glioma - pathology Humans Magnetics Medical sciences Nanoparticles - administration & dosage Neurology Paclitaxel - administration & dosage Paclitaxel - chemistry Paclitaxel - metabolism Rats Rats, Sprague-Dawley Solubility Tumors Tumors of the nervous system. Phacomatoses Xenograft Model Antitumor Assays |
| title | Magnetic Paclitaxel Nanoparticles Inhibit Glioma Growth and Improve the Survival of Rats Bearing Glioma Xenografts |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T20%3A29%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Magnetic%20Paclitaxel%20Nanoparticles%20Inhibit%20Glioma%20Growth%20and%20Improve%20the%20Survival%20of%20Rats%20Bearing%20Glioma%20Xenografts&rft.jtitle=Anticancer%20research&rft.au=Zhao,%20Ming&rft.date=2010-06-01&rft.volume=30&rft.issue=6&rft.spage=2217&rft.epage=2223&rft.pages=2217-2223&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E734005564%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734005564&rft_id=info:pmid/20651372&rfr_iscdi=true |